'Micro-organ' startup Stemonix agrees to merger with public pharma company
Stemonix will receive about 78% of Cancer Genetics' 2.31 million outstanding shares, making it the majority owner of the company. At Cancer Genetics's press time share price of around $7, the transaction will be worth $12.6 million to Stemonix.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Carrigan Miller Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Genetics | Health Management | Mergers and Aquisitions | Pharmaceuticals